Purpose
|
Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar®. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy.
|
Characteristics
|
Tradename: TEQUIN Source of Compound: synthetic, BMS-206584-01, AM-1155, ethanolamine salt Target: Topoisomerase inhibitor Receptor: Topoisomerase IV Status: USAN, INN
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
98 %
|
Formula
|
C19H22FN3O4
|
Solubility
|
Water: 60 mg/mL (at pH 4)
|